Cost-effectiveness Analysis of Replacing the 10-valent Pneumococcal Conjugate Vaccine (PCV10) with the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Brazil Infants

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2020 Sep 23

PMID 32966176

Citations 5

Authors

Johnna Perdrizet

Carlos Felipe S Santana

Thais Senna

Rodrigo Fernandes Alexandre

Rodrigo Sini de Almeida

Julia Spinardi

Matt Wasserman

Affiliations

Soon will be listed here.

Abstract

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PCV13). We sought to evaluate the cost-effectiveness and budget impact of switching from PCV10 to PCV13 for Brazilian infants from a payer perspective. A decision-analytic model was adapted to evaluate the clinical and economic outcomes of continuing PCV10 or switching to PCV13. The analysis estimated future costs ($BRL), quality-adjusted life-years (QALYs), and health outcomes for PCV10 and PCV13 over 5 y. Input parameters were from published sources. Future serotype dynamics were predicted using Brazilian and global historical trends. Over 5 y, PCV13 could prevent 12,342 bacteremia, 15,330 meningitis, 170,191 hospitalized pneumonia, and 25,872 otitis media cases, avert 13,709 pneumococcal disease deaths, gain 20,317 QALYs, and save 172 million direct costs compared with PCV10. The use of PCV13 in the Brazilian NIP could reduce pneumococcal disease, improve population health, and save substantial health-care costs. Results are reliable even when considering uncertainty for possible serotype dynamics with different underlying assumptions.

Citing Articles

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.

Wilson M, McDade C, Beby-Heijtel A, Waterval-Overbeek A, Sundaram V, Perdrizet J Infect Dis Ther. 2023; 12(7):1809-1821.

PMID: 37318710 PMC: 10390433. DOI: 10.1007/s40121-023-00828-8.

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.

Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S Infect Dis Ther. 2023; 12(3):933-950.

PMID: 36774428 PMC: 9922201. DOI: 10.1007/s40121-023-00767-4.

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.

Sevilla J, Burnes D, El Saie R, Haridy H, Wasserman M, Pugh S Hum Vaccin Immunother. 2022; 18(6):2114252.

PMID: 36070504 PMC: 9746463. DOI: 10.1080/21645515.2022.2114252.

Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

Perdrizet J, Horn E, Nua W, Perez-Peralta J, Nailes J, Santos J Infect Dis Ther. 2022; 11(4):1763-1765.

PMID: 35575973 PMC: 9334460. DOI: 10.1007/s40121-022-00641-9.

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".

Gomez J, Pinto T, Nieto Guevara J, Noronha T Hum Vaccin Immunother. 2021; 18(1):1894898.

PMID: 34010099 PMC: 8920202. DOI: 10.1080/21645515.2021.1894898.

References

Shafie A, Ahmad N, Naidoo J, Foo C, Wong C, Pugh S . Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Hum Vaccin Immunother. 2020; 16(7):1719-1727. PMC: 7482775. DOI: 10.1080/21645515.2019.1701911. View

Temple B, Trong Toan N, Thi Trang Dai V, Bright K, Licciardi P, Marimla R . Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial. Lancet Infect Dis. 2019; 19(5):497-509. PMC: 6484092. DOI: 10.1016/S1473-3099(18)30734-5. View

Hanquet G, Krizova P, Valentiner-Branth P, Ladhani S, Nuorti J, Lepoutre A . Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2018; 74(5):473-482. PMC: 6484683. DOI: 10.1136/thoraxjnl-2018-211767. View

Harboe Z, Dalby T, Weinberger D, Benfield T, Molbak K, Slotved H . Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8):1066-73. DOI: 10.1093/cid/ciu524. View

Lo S, Gladstone R, van Tonder A, Lees J, du Plessis M, Benisty R . Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019; 19(7):759-769. PMC: 7641901. DOI: 10.1016/S1473-3099(19)30297-X. View

Levy C, Ouldali N, Caeymaex L, Angoulvant F, Varon E, Cohen R . Diversity of Serotype Replacement After Pneumococcal Conjugate Vaccine Implementation in Europe. J Pediatr. 2019; 213:252-253.e3. DOI: 10.1016/j.jpeds.2019.07.057. View

Varghese J, Chochua S, Tran T, Walker H, Li Z, Snippes Vagnone P . Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2019; 26(4):512.e1-512.e10. DOI: 10.1016/j.cmi.2019.09.008. View

Melegaro A, Edmunds W . Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004; 22(31-32):4203-14. DOI: 10.1016/j.vaccine.2004.05.003. View

Rupp R, Hurley D, Grayson S, Li J, Nolan K, McFetridge R . A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019; 15(3):549-559. PMC: 6988874. DOI: 10.1080/21645515.2019.1568159. View

10.

Cassiolato A, Almeida S, Andrade A, Minamisava R, Brandileone M . Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS One. 2018; 13(11):e0208211. PMC: 6264150. DOI: 10.1371/journal.pone.0208211. View

11.

Brandileone M, Almeida S, Minamisava R, Andrade A . Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018; 36(19):2559-2566. DOI: 10.1016/j.vaccine.2018.04.010. View

12.

Desmet S, Peetermans W, Lagrou K . Switch in childhood pneumococcal vaccine in Belgium. Lancet Infect Dis. 2018; 18(9):945-946. DOI: 10.1016/S1473-3099(18)30484-5. View

13.

Novaes H, Sartori A, de Soarez P . Hospitalization rates for pneumococcal disease in Brazil, 2004 - 2006. Rev Saude Publica. 2011; 45(3):539-47. DOI: 10.1590/s0034-89102011005000028. View

14.

Wijmenga-Monsuur A, van Westen E, Knol M, Jongerius R, Zancolli M, Goldblatt D . Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants. PLoS One. 2015; 10(12):e0144739. PMC: 4690595. DOI: 10.1371/journal.pone.0144739. View

15.

Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A . Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens. 2020; 9(2). PMC: 7168640. DOI: 10.3390/pathogens9020076. View

16.

Janoir C, Lepoutre A, Gutmann L, Varon E . Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France. Open Forum Infect Dis. 2016; 3(1):ofw020. PMC: 4777900. DOI: 10.1093/ofid/ofw020. View

17.

Kawai K, Adil E, Barrett D, Manganella J, Kenna M . Ambulatory Visits for Otitis Media before and after the Introduction of Pneumococcal Conjugate Vaccination. J Pediatr. 2018; 201:122-127.e1. DOI: 10.1016/j.jpeds.2018.05.047. View

18.

Gomez J, Abreu A, Caceres D, Nieto J, Ortega-Barria E . Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil. Pediatr Infect Dis J. 2019; 38(10):e260-e265. DOI: 10.1097/INF.0000000000002436. View

19.

Mittmann N, Trakas K, Risebrough N, Liu B . Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999; 15(4):369-76. DOI: 10.2165/00019053-199915040-00004. View

20.

Wilson M, Wasserman M, Jadavi T, Postma M, Breton M, Peloquin F . Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infect Dis Ther. 2018; 7(3):353-371. PMC: 6098750. DOI: 10.1007/s40121-018-0206-1. View